Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mechanistic Models: Compartment Models in Algorithms for Numerical Problem Solving01:29

Mechanistic Models: Compartment Models in Algorithms for Numerical Problem Solving

56
Mechanistic models play a crucial role in algorithms for numerical problem-solving, particularly in nonlinear mixed effects modeling (NMEM). These models aim to minimize specific objective functions by evaluating various parameter estimates, leading to the development of systematic algorithms. In some cases, linearization techniques approximate the model using linear equations.
In individual population analyses, different algorithms are employed, such as Cauchy's method, which uses a...
56
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

130
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
130
Regression Toward the Mean01:52

Regression Toward the Mean

6.3K
Regression toward the mean (“RTM”) is a phenomenon in which extremely high or low values—for example, and individual’s blood pressure at a particular moment—appear closer to a group’s average upon remeasuring. Although this statistical peculiarity is the result of random error and chance, it has been problematic across various medical, scientific, financial and psychological applications. In particular, RTM, if not taken into account, can interfere when...
6.3K
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

149
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
149
Actuarial Approach01:20

Actuarial Approach

79
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
79
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

195
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
195

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies for Patients with COPD and Phenotypic Features of Asthma: A Pooled Post Hoc Analysis of KRONOS and ETHOS.

International journal of chronic obstructive pulmonary disease·2024
Same author

Benefits of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate on COPD Exacerbations, Lung Function, Symptoms, and Quality of Life Across Blood Eosinophil Ranges: A Post-Hoc Analysis of Data from ETHOS.

International journal of chronic obstructive pulmonary disease·2022
Same author

Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Exacerbation Outcomes in Patients with COPD without a Recent Exacerbation History: A Subgroup Analysis of KRONOS.

International journal of chronic obstructive pulmonary disease·2021
Same author

The attributable estimand: A new approach to account for intercurrent events.

Pharmaceutical statistics·2020
Same author

Fibrinogen does not relate to cardiovascular or muscle manifestations in COPD: cross-sectional data from the ERICA study.

Thorax·2018
Same author

Impact of a five-dimensional framework on R&D productivity at AstraZeneca.

Nature reviews. Drug discovery·2018

Related Experiment Video

Updated: Jul 7, 2025

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.5K

Algorithmic benchmark modulation: A novel method to develop success rates for clinical studies.

Bart Ja Willigers1, Sridevi Nagarajan1,2, Serban Ghiorghui1

  • 1AstraZeneca, Cambridge, UK.

Clinical Trials (London, England)
|December 21, 2023
PubMed
Summary
This summary is machine-generated.

AstraZeneca developed a structured algorithm to improve Probability of Technical Success (PTS) assessments for clinical trials. This new method, validated against historical data, aims for more consistent and efficient PTS evaluations in pharmaceutical decision-making.

Keywords:
Clinical trialassurance calculationbenchmarkingprobability of successquantitative decision making

More Related Videos

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.5K
A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM
13:54

A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM

Published on: August 18, 2023

4.6K

Related Experiment Videos

Last Updated: Jul 7, 2025

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.5K
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.5K
A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM
13:54

A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM

Published on: August 18, 2023

4.6K

Area of Science:

  • Pharmaceutical industry
  • Clinical trial management
  • Decision analysis

Background:

  • Accurate Probability of Technical Success (PTS) is crucial for pharmaceutical decision-making.
  • Current methods for estimating PTS include power calculations, assurance calculations, and industry benchmarks, often with subjective adjustments.
  • AstraZeneca utilized both assurance calculations and industry benchmarks, incorporating subjective modulations.

Purpose of the Study:

  • To introduce and validate a novel, structured algorithm for modulating Probability of Technical Success (PTS) values.
  • To enhance the consistency and efficiency of PTS assessments in pivotal pharmaceutical studies.
  • To provide a tool that assists the pharmaceutical industry in addressing challenges in PTS estimation.

Main Methods:

  • Development of a simple algorithm based on a comprehensive set of multiple-choice questions for PTS modulation.
  • The algorithm structures issues historically considered during subjective modulations.
  • Validation involved a set of 57 phase 3 PTS assessments.

Main Results:

  • AstraZeneca's historical PTS estimations were found to be reasonably accurate based on 57 phase 3 assessments.
  • A strong correlation was observed between subjective modulations and the novel modulation algorithm.
  • The findings provide confidence in the validity of the new PTS modulation method.

Conclusions:

  • The PTS modulation algorithm addresses limitations of traditional assurance calculations and unmodulated benchmarks, such as selection biases and difficulty in modeling various factors.
  • It allows for the accommodation of project-specific considerations, unlike generic industry benchmarks.
  • This methodology enables more consistent PTS assessments with reduced effort for pivotal studies.